Department of Pharmaceutical and Pharmacological Sciences, University of Padova, Padova, Italy.
Foundation for Biology and Regenerative Medicine, Tissue Engineering and Signaling (TES) ONLUS, Padova, Italy.
J Cell Mol Med. 2018 Mar;22(3):1840-1854. doi: 10.1111/jcmm.13468. Epub 2018 Jan 5.
The wound healing is a complex process wherein inflammation, proliferation and regeneration evolve according to a spatio-temporal pattern from the activation of coagulation cascade to the formation of a plug clot including fibrin matrix, blood-borne cells and cytokines/growth factors. Creating environments conducive to tissue repair, the haemoderivatives are commonly proposed for the treatment of hard-to-heal wounds. Here, we explored in vitro the intrinsic regenerative potentialities of a leucocyte- and platelet-rich fibrin product, known as CPL-MB, defining the stemness grade of cells sprouting from the haemoderivative. Using highly concentrated serum-based medium to simulate wound conditions, we isolated fibroblast-like cells (CPL-CMCs) adhering to plastic and showing stable in vitro propagation, heterogeneous stem cell expression pattern, endothelial adhesive properties and immunomodulatory profile. Due to their blood derivation and expression of CXCR4, CPL-CMCs have been suggested to be immature cells circulating in peripheral blood at quiescent state until activation by both coagulation event and inflammatory stimuli such as stromal-derived factor 1/SDF1. Expressing integrins (CD49f, CD103), vascular adhesion molecules (CD106, CD166), endoglin (CD105) and remodelling matrix enzymes (MMP2, MMP9, MMP13), they showed a transendothelial migratory potential besides multipotency. Taken together, our data suggested that a standardized, reliable and economically feasible blood product such as CPL-MB functions as an artificial stem cell niche that, under permissive conditions, originate ex vivo immature cells that could be useful for autologous stem cell-based therapies.
伤口愈合是一个复杂的过程,其中炎症、增殖和再生根据时空模式从凝血级联的激活演变为包括纤维蛋白基质、血液来源细胞和细胞因子/生长因子的塞栓形成。为了创造有利于组织修复的环境,血液衍生产品通常被提议用于治疗难以愈合的伤口。在这里,我们研究了一种白细胞和血小板丰富的纤维蛋白产品 CPL-MB 的内在再生潜力,定义了从血液衍生产品中萌发的细胞的干性等级。使用高度浓缩的基于血清的培养基模拟伤口条件,我们分离出贴附于塑料的成纤维样细胞(CPL-CMCs),并表现出稳定的体外增殖、异质性干细胞表达模式、内皮黏附特性和免疫调节特征。由于其血液来源和 CXCR4 的表达,CPL-CMC 被认为是在静息状态下循环于外周血中的未成熟细胞,直到被凝血事件和炎症刺激(如基质衍生因子 1/SDF1)激活。CPL-CMC 表达整合素(CD49f、CD103)、血管黏附分子(CD106、CD166)、内胚层蛋白(CD105)和重塑基质酶(MMP2、MMP9、MMP13),除了多能性外,它们还具有跨内皮迁移潜力。总之,我们的数据表明,标准化、可靠且经济可行的血液产品(如 CPL-MB)可以作为人工干细胞龛,在允许的条件下,从体外产生未成熟的细胞,这些细胞可能对基于自体干细胞的治疗有用。